2023-08-09 07:56:21 ET
- Adaptimmune press release ( NASDAQ: ADAP ): Q2 GAAP EPS of -$0.02 beats by $0.19 .
- Revenue of $5.13M (-7.4% Y/Y) misses by $1.54M .
- The Company believes that its existing cash, cash equivalents and marketable securities, together with the additional payments under the Strategic Collaboration and License Agreement with Genentech and payments under the Termination and Transfer Agreement with GSK, will fund the Company's current operations into early 2026
For further details see:
Adaptimmune GAAP EPS of -$0.02 beats by $0.19, revenue of $5.13M misses by $1.54M